PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
19718660-5	2009	Spreading of cancer cells on fibronectin does not require de novo transcription but is sensitive to cycloheximide, an inhibitor of protein synthesis.	Cycloheximide	100-113	fibronectin 1	Homo sapiens	29-40	
9259353-10	1997	Addition of cycloheximide, a protein synthesis inhibitor, upregulated PAF-induced fibronectin mRNA expression but downregulated PAF-induced TGF-beta1 gene expression, suggesting the existence of different regulatory transcriptional factors of the two proteins.	Cycloheximide	12-25	fibronectin 1	Homo sapiens	82-93	
15193149-8	2004	The induction of FN was significantly down-regulated in response to the adenosine receptor antagonist alloxazine and was inhibited by cycloheximide.	Cycloheximide	134-147	fibronectin 1	Homo sapiens	17-19	
18359077-6	2008	The QCM-D was able to detect differences in the untreated cellular responses to fibronectin versus serum precoated Ta and PS(ox) substrates, while cycloheximide treatment of the cells produced the same QCM-D response for fibronectin and serum precoatings on each of the materials.	Cycloheximide	147-160	fibronectin 1	Homo sapiens	221-232	
15652337-2	2005	Using myocilin produced in sf9 insect cells, myocilin inhibited spreading of cycloheximide-treated human skin fibroblasts plated on substrates co-coated with myocilin and either fibronectin or its Heparin II domain.	Cycloheximide	77-90	fibronectin 1	Homo sapiens	178-189	
15525600-5	2004	Blockade of protein synthesis by cycloheximide almost completely inhibited the concomitant induction of FN mRNA by T3, indicating that T3 indirectly regulates FN.	Cycloheximide	33-46	fibronectin 1	Homo sapiens	104-106	
10930408-4	2000	Cyclic stretch induced an increase in vascular fibronectin mRNA levels that was inhibited by actinomycin D and CV11974, an angiotensin II type 1 receptor antagonist; cycloheximide and PD123319, an angiotensin II type 2 receptor antagonist, did not affect the induction.	Cycloheximide	166-179	fibronectin 1	Homo sapiens	47-58	
10640397-2	2000	Fibronectin can provide sufficient signals for all three processes, even when protein synthesis is prevented by cycloheximide.	Cycloheximide	112-125	fibronectin 1	Homo sapiens	0-11	
8670569-6	1996	Proteoglycan-degrading activity related to the 40 kDa Fn fragment was decreased up to 66% by fetal calf serum (10%), but was not prevented by protein synthesis inhibitors (cycloheximide or actinomycin D).	Cycloheximide	172-185	fibronectin 1	Homo sapiens	54-56	
9141628-5	1997	Cells treated with cycloheximide and monensin, to limit the synthesis and secretion of endogenous fibronectin, attached as well as untreated cells.	Cycloheximide	19-32	fibronectin 1	Homo sapiens	98-109	
8621982-5	1996	An increase in new protein synthesis appeared to account for part of the increased fibronectin, because the inhibitor of protein synthesis, cycloheximide, inhibited the increase in total production of fibronectin.	Cycloheximide	140-153	fibronectin 1	Homo sapiens	83-94	
8621982-5	1996	An increase in new protein synthesis appeared to account for part of the increased fibronectin, because the inhibitor of protein synthesis, cycloheximide, inhibited the increase in total production of fibronectin.	Cycloheximide	140-153	fibronectin 1	Homo sapiens	201-212	
8218108-3	1993	Increased binding was evident within 10 minutes of treatment of cycloheximide-treated cells with LPA and was due to an increase in the number of fibronectin binding sites.	Cycloheximide	64-77	fibronectin 1	Homo sapiens	145-156	
8061052-8	1994	Cycloheximide also inhibited FN release, but this inhibition was additive to that with monensin.	Cycloheximide	0-13	fibronectin 1	Homo sapiens	29-31	
8069931-10	1994	The effects of fibronectin/RGDS were blocked by actinomycin D and cycloheximide.	Cycloheximide	66-79	fibronectin 1	Homo sapiens	15-26	
8006027-7	1994	Incorporation of d70 kDa into the extracellular matrix was dependent upon protein synthesis; in cycloheximide-treated cultures that lacked a pre-existing matrix, d70 kDa accumulated in the extracellular matrix only in the presence of intact fibronectin.	Cycloheximide	96-109	fibronectin 1	Homo sapiens	241-252	
2114411-5	1990	In cultures incubated in the presence of cycloheximide, plasma fibronectin was bound to the cell surface and was assembled into extracellular fibrils.	Cycloheximide	41-54	fibronectin 1	Homo sapiens	63-74	
1427413-2	1992	In both amnion and placental tissues, cycloheximide inhibited the fibronectin output indicating that it was being synthesized.	Cycloheximide	38-51	fibronectin 1	Homo sapiens	66-77	
2046332-6	1991	Cycloheximide experiments provided evidence that the TGF-beta 1-elicited upregulation of the expression of the fibronectin gene is, but that of type IV collagen is not, entirely dependent on protein synthesis, suggesting two different mechanisms for enhancement of gene expression.	Cycloheximide	0-13	fibronectin 1	Homo sapiens	111-122	
3054513-8	1988	The second phase of the biphasic effect and the increase in soluble cellular fibronectin were blocked by cycloheximide.	Cycloheximide	105-118	fibronectin 1	Homo sapiens	77-88	
2407710-3	1990	The total content of fibronectin in endothelial cells exposed to flow was found to be lower than that in static controls after periods of 12 to 48 h. In the presence of cycloheximide there was no difference in the fibronectin content of sheared and unsheared cells.	Cycloheximide	169-182	fibronectin 1	Homo sapiens	21-32	
2950120-5	1987	Dexamethasone-induced fibronectin binding to HT-1080 cells was time dependent, dose dependent, and inhibited by cycloheximide.	Cycloheximide	112-125	fibronectin 1	Homo sapiens	22-33	
3125175-10	1988	In contrast, the induction of fibronectin, beta-actin, and type I procollagen (synthesized only in WI-38 cells) was abrogated by cycloheximide.	Cycloheximide	129-142	fibronectin 1	Homo sapiens	30-41	
3539950-7	1986	However, when HUVEC were exposed to 2.5 or 25 micrograms ml-1 of cycloheximide for 4 h before and during the adherence assays, the adherence to fibronectin was 50-200% greater than to types I and III collagen.	Cycloheximide	65-78	fibronectin 1	Homo sapiens	144-155	
3539950-11	1986	In the presence of cycloheximide anti-fibronectin antibodies totally blocked HUVEC adherence.	Cycloheximide	19-32	fibronectin 1	Homo sapiens	38-49